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Using generic medications for chronic diseases provides efficacy similar to that of brand-name medication use, but at a 
lower price, potentially enhancing adherence. However, previous studies show that disadvantaged people, who may 
particularly benefit from cost savings, have low trust of generics and increased reluctance to switch to generics. The 
rural South includes areas of high poverty and minority communities whose members are at high risk for poor health 
outcomes; however, whether such beliefs exist in these communities has not been reported. We sought to obtain 
qualitative insight into beliefs about generic medication use among African Americans in the rural South.
Methods 
Investigators conducted 4 focus groups with 30 community members from Alabama’s Black Belt area. Transcribed 
discussions were analyzed and common themes identified.
Results 
Participants were primarily unemployed middle-aged women, one-fourth of whom were uninsured and more than half 
of whom had a high school education or less. Barriers to generic medication use included perceptions that generics are 
less potent than brand-name medications, require higher doses, and, therefore, result in more side effects; generics are 
not “real” medicine; generics are for minor but not serious illnesses; the medical system cannot be trusted; and poor 
people are forced to “settle” for generics.
Conclusion 
Although education about generics could rectify misinformation, overcoming views such as mistrust of the medical 
system and the sense of having to settle for generics because of poverty may be more challenging. Policy makers and 
providers should consider these perspectives when working to increase generic drug use in these populations.
Introduction
The bioequivalence of generic and brand medications coupled with substantially lower cost make increasing generic 
medication use, especially for people with chronic diseases, a health care priority (1-4). Lowering cost can improve 
adherence; nevertheless, generic medications are underused (1,4).
Multiple factors contribute to generic drug use, including systems-level factors, such as insurance restrictions or state 
generic substitution laws; provider-level factors, such as physician beliefs or practices (1,5); and patient-level factors, 
such as consumer perceptions. Negative perceptions of generic medications are higher among the elderly, minorities, 
and people with low socioeconomic status and health literacy (6,7). Compared with white New Yorkers, African 
American New Yorkers were more reluctant to switch to generics and had more worries about side effects, medication 
dependency, and potential harms of generic substitutes (6). Australian patients less frequently used generics for 
chronic or serious illnesses such as diabetes than for minor illnesses such as allergies (8). Communication with 
Page 1 of 8CDC - Preventing Chronic Disease: Volume 9, 2012: 12_0010
physicians about generics and comfort with generic substitution significantly increased generic use, demonstrating 
that such barriers could be overcome (9,10).
Beliefs about generic medication safety and efficacy may be particularly relevant in the rural South, a geographic 
region characterized by high chronic disease prevalence and the highest stroke and coronary heart disease mortality in 
the United States (11,12). The excess mortality risk is highest for African Americans, who also live in the rural South in 
higher numbers than in any other rural area of the United States (11). In the Alabama Black Belt, one-third of residents 
live below the federal poverty line, 1 in 3 African Americans older than 50 years have diabetes, and more than half are 
overweight or obese (13). Increasing generic medication use in residents of these areas could benefit their health. 
However, to our knowledge, no studies have reported on perceptions regarding generic medications among rural 
Southern African Americans with chronic diseases.
In a diabetes intervention trial conducted in Alabama’s Black Belt, we found that many participants used brand-name 
diabetes medications despite reporting limited income (14,15). We conducted focus groups with area residents who 
were taking at least 1 medication for chronic disease to better understand beliefs about generic medications.
Methods
The study was conducted in 2 counties in the rural Alabama Black Belt during 2011. Focus group participants were 
recruited by using personal contact by community-based staff at a diabetes research program (14,15). These 
community coordinators serve as local liaisons and have widely established contact networks. Investigators followed 
up contacts by community coordinators with eligibility screening via telephone who ensured that focus group members 
were aged 18 or older, Black Belt residents, African American, and taking at least 1 daily medication for hypertension, 
diabetes, or another chronic disease. The University of Alabama at Birmingham institutional review board approved 
the study protocol.
Four focus groups totaling 30 participants met in Wilcox and Perry Counties in local community centers. Investigators 
collected anonymous demographic data at the beginning of each focus group, using simplified forms and verbal 
instructions. Assisted by a note taker, the moderator used a script (Appendix) to guide the discussion and audio-
recorded each group session, which lasted 30 to 60 minutes. Participants received a $10 gift card and dinner as 
compensation for participation.
Transcripts were imported into NVivo version 9 (QSR International, Cambridge, Massachusetts) qualitative software 
for data analysis. Two authors (K.S., E.L.) independently reviewed transcripts, identifying major themes or codes. 
Initial themes were discussed until authors agreed on major themes. Once the codebook was established, the 2 authors 
coded all transcripts and resolved differing opinions through discussion. By the fourth focus group, no new themes 
emerged, suggesting saturation had been reached.
Results
Participants were predominantly middle-aged women (Table 1); 13 (43%) graduated from college, and 4 had less than 
a high school education. Twenty-two participants (73%) were unemployed, and one-quarter were uninsured. However, 
only 6 participants had no source of usual care or used the emergency department as their usual source of care. More 
than 40% of participants took 6 or more medications daily for chronic diseases.
Theme 1: perceived differences in efficacy
Perceived differences in generic and brand name medication efficacy were commonly expressed (Table 2). In all but 1 
group, generics were strongly perceived as being less effective or potent than brand names. Asked to define generics, 1 
participant answered, “Not as good as the real medicine” (group B, woman). Other participants stated, “Generic 
medicine is less potent . . . other medicine is stronger” (group B, woman) and “Name brand is more powerful than the 
generic” (group D, woman). One participant commented,
A lot of times, the doctor gives you a sample and it is the brand name. But when you go to get the medicine, it 
is too expensive, so you end up with the generic. You can really tell the difference . . . just how effective they 
are. (group B, woman)
Asked if they would always buy brand medications if they could afford it, several participants in each group responded 
they would because the brand name was more effective.
Several participants likened this efficacy difference to that between generic and brand-name groceries. One participant 
noted,
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People always say you buy Domino sugar. It’s the best. Don’t buy the cheap brand. Buy Domino and you won’t 
have to use as much. . . . Domino’s is sweeter. Generic medicine is not as effective as, you know, the real 
medicine prescriptions, the strength. (group B, woman)
Other participants did not express this belief and shared positive personal experiences with generics: “I take all 
generics and mine work fine” (group A, woman) and “They just don’t have the name brand, but they do the 
same” (group D, woman). Several participants received reassurance about generic equivalence from pharmacists or 
physicians. “We have a good pharmacist . . . and he’ll let you know whether this medicine work[s] or if the generic is 
cheaper, he’ll say . . . but it do the same thing as the . . . name brand” (group A, woman).
Theme 2: perceived differences in side effects
Fewer participants expressed concerns about increased side effects as a reason for their hesitancy to use generic 
medications. Some participants felt that because of their lower potency, generics must be made stronger to be equally 
effective as the brand-name drugs, leading to more side effects. One participant stated,
Being generic, they have more in it to make it stronger and they might use more synthetic[s] and . . . you 
might get more of a headache or you might get a little more dizzy or you feel more light-headed. Or sometimes 
generic can be little bit more of a risk for side effects. It depending on . . . which generic you’re taking. ’Cause 
everyone cannot take generic. (group B, woman)
Participants related that their friends and family members were also reluctant to use generics. One participant 
reported,
[My friend] was saying that [the] generic medicine she was taking was not as good as the regular medicine, 
and she would go back to the doctor to tell him because she was having a bad effect and wanted off the 
medicine she was taking and she wanted the regular doses of the regular. (group B, woman)
Another participant’s sister believed that the generic would interact negatively with her other medications: “She didn’t 
want the . . . generic medication[s] . . . because she felt like they would . . . contradict all of the medicines that she was 
taking easier if they were generic as opposed to being formulary or the brand name” (group B, woman).
Many participants were concerned about possible side effects of both brand and generic medications: “If you read the 
side effects, you wouldn’t take nothing. . . . All of them have side effects” (group B, woman). Another participant stated, 
“Some of the side effects, you read that’s on the medicine is more scary than taking it. . . . It scares you a little bit. . . . [I 
do] not want to take them” (group D, woman). One participant reported that she and her family did not administer her 
mother’s heart medication because of the listed side effects (group B, woman).
The belief that generics were not suitable for everyone was a theme voiced in all 4 groups: “Some brand medicines are 
good for some people. . . . Just depends on the person and their system” (group B, woman), and “Yes, it depends on the 
person. If I can’t take the brand name . . . then sometimes I’ll take the generic. If I can’t take generic, I’ll take the brand 
name” (group B, woman). Another participant stated, “See, everyone cannot take generics. They have to have a 
prescribed medication” (group B, woman).
Theme 3: perceptions that generics are not real medicines
When asked to define brand name medications, participants commonly referred to them as the “real thing” in contrast 
to their idea of generics (eg, “Something like an off brand from the real thing” [group C, woman], and, “Not the real 
stuff” [group C, woman]). Another participant said, “If money wasn’t an issue for me, I’d get the real deal” (group D, 
woman). One participant’s comment was widely supported: “I hope they lower the price of real drugs so people can 
afford to buy them” (group D, woman).
Theme 4: willingness to use generics for minor but not serious illness
Participants expressed willingness to use generics for minor illnesses such as allergies and colds but were reluctant to 
do so for serious diseases. For example, 1 participant would not take generic antihypertensive medications because 
“High blood pressure is very dangerous. You don’t want to risk your health or your life because of the cost” (group B, 
woman). When asked about hypothetical generic cancer medications, another participant stated, “My dad has cancer 
now and I don’t know [about] the cheaper products. I want the best that you know you can get. ’Cause cancer is no 
joke, that’s serious business” (group B, woman). Another participant echoed this view: “I’ll pay top dollar for that 
because I know I want to live” (group D, woman).
When asked whether they would choose generic or brand name if they could afford anything, only 1 participant said 
she would choose generics, “because I am a penny-pincher” (group D, woman). Others said they would choose brand-
name medications: “I would go for the best” (group C, woman) and “If money wasn’t a problem, I would go for the 
brand” (group C, woman).
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Theme 5: trust in the medical system
Many participants reported stopping medications against their doctor’s advice, expressing mistrust of the doctor’s 
abilities or a hidden financial motive. Many participants noted that “You know more about your body than your doctor 
does.” One participant stopped her medication because she believed her doctor had inaccurately diagnosed her.
I had one I took myself off of. Thyroid pill. And all other doctors I went to never told me I had thyroid 
problems. I think that’s something he tried to put on me. And I just stopped taking them because the rest of 
them didn’t tell me. (group C, woman)
One participant discontinued a medication when she learned that it was an antidepressant, which her doctor had not 
discussed with her. She viewed this as a reason to mistrust her physician’s prescription choices.
They had me on antidepression medicine. . . . That’s the last thing on my list I be needing. . . . From then on, 
they gave me a wake-up call. . . . I started looking at any kind of medicine they give me. I look in my book and 
look up and see what it’s really for. (group C, woman)
Many participants expressed concerns about their relationships with doctors, and some distrusted their doctor’s 
prescription choices. This distrust stemmed from their belief that doctors were influenced by financial incentives 
provided by pharmaceutical companies: “Some doctors are pill pushers” (group B, woman) and “The more pills they 
push, the more money they make” (group B, woman). Another participant hypothesized, “I don’t know if it’s true or not 
that every prescription that the doctor write, they get a percentage. And so, whether it’s true or not, they sure love to 
write” (group B, woman), to which another responded, “I think it’s true, too, because they be glad to see the 
pharmaceuticals come. They invited them in between the patients” (group B, woman).
Group B participants in particular discussed the effect on physician prescribing of the pharmaceutical companies’ use 
of meals and attractive representatives. A participant noted, “Ever notice those pharmaceutical reps, most of them are 
nice-looking young ladies or good-looking young men. They dress very well, heels on” (group B, woman). Another 
responded, “They (pharmaceutical representatives) will wine and dine them to more or less guarantee that the doctor 
will push their medicine” (group B, woman). Asked whether money influences doctors’ prescriptions, many 
participants emphatically said yes. “We know doctors go to school. . . . You know they’re well educated. . . . But we 
know money plays a big part in everything” (group B, woman).
Theme 6: perception of “having to settle” for generic medications if you are 
poor
Finances were a substantial part of group discussions. Almost every participant knew that generics were cheaper. 
However, many participants felt that poor people must “settle” for generic medications. Some associated “settling” 
with being African American. “The reason being that black Americans take generic ’cause we can’t afford all the name-
brand medication,” stated a group B female participant. “A lot of times, we as black Americans go back [to generic 
medications] because we can’t afford [brand-name medications],” said another group B woman. “They never have 
nothing cheap. But we settle for that because we’re trying to do the best we can with the fixed income we have.” Some 
said that generics were mainly geared toward poor people. “Only people that’s worried about that is people that have 
financial problems. . . . They need the generic brand” (group D, woman). Another group D woman said, “Now, if money 
wasn’t an issue for me . . . it would never cross my mind about generic.”
Settling for cheaper, second-choice medications was tied to feelings of low-income patients being at the “mercy” of the 
medical industry. “I think that the doctors and manufacturers use us as guinea pigs to see which ones we will buy the 
most,” stated one group B woman. “That’s why you are letting the poor people have it. Because we can’t afford it,” said 
another group B woman. “It’s all about money and the poor people are the ones that have to suffer, and they [drug 
companies] smile all the way to the bank,” said a third participant (group C, woman). Asked for which illnesses 
participants would not feel comfortable taking generics, a participant stated, “Cancer medication, I would have to 
spend the money. I want to live. . . . That’s where they smart, they make that money because they know you want to 
live” (group D, woman).
Several participants perceived a discrepancy between physician prescribing and insurance coverage, believing that 
insurance companies forced them to take generics against the doctor’s judgment to save costs: “I think my doctor 
would have me on all brand-name drugs. But it is the insurance, he put me on the brand name and they say you’ve got 
to change to generic. So, I take generic ’cause I can’t afford all brand names” (group A, woman). Another participant 
expressed frustration with insurance companies’ ability to overrule doctors’ choices: “Doctors, they prescribe the name 
brand drugs. Insurance companies saying generic. So if the doctor is going to be a doctor, why is the insurance 
company telling the doctor what to do?” (group A, woman).
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Discussion
In this qualitative study, barriers to generic medication use included beliefs about generic medications having lower 
safety and efficacy and deeper feelings of mistrust of the medical system. Although health education can provide 
consumers with accurate information regarding the efficacy and safety of generic medications, addressing medication-
related beliefs resulting from negative experiences with the medical system, such as mistrust of providers, insurers, or 
pharmaceutical companies, may be more difficult.
Our findings indicated that residents with chronic disease in the rural Black Belt held some beliefs regarding generic 
medications and their use similar to those of people living elsewhere, but literature in the United States on this topic is 
limited. Elderly hospitalized New Yorkers were more likely to hold negative beliefs if they were nonwhite and had low 
health literacy (6). A national survey found no differences in beliefs about generic medications by race, and 
approximately 25% of respondents believed that brand-name drugs were more effective than generics (16). Recent 
reports on this topic have originated primarily from countries other than the United States and revealed themes 
similar to some of those we described (17); Australians were more willing to switch to generic medications for minor 
illnesses but not for serious illnesses (8), and Portuguese respondents believed that generics were not as good as 
brands for serious illnesses (18). The issues of mistrust we described were not reported in other studies of attitudes 
toward generic medication.
Our study has limitations. Our study population was limited to 2 counties in Alabama’s Black Belt, and participants’ 
views may not fully represent the views of residents of Alabama and other Black Belt states. Furthermore, although 
participant race was representative of Wilcox and Perry counties, participants reported higher educational levels and 
93% were women, characteristics that may affect generalizability. Although we conducted only 4 focus groups with 30 
participants, the lack of new themes emerging by the fourth group suggested that we had reached saturation. By using 
the community infrastructure of an established research program, we may have enhanced the likelihood of disclosure, 
because participants were relatives and friends of the community-based research staff. However, these participants 
also may have been more favorably inclined toward research and the health care system than others in their 
community. 
We found that African Americans with chronic diseases living in an impoverished rural Southern region of the United 
States held beliefs regarding generic medications that may contribute to underuse of these medications. Physicians 
caring for such patients may find these results helpful in guiding their discussion with patients on generic medications. 
The results of our study also may be useful for policy makers and public health professionals seeking to enhance 
generic medication use in similar populations.
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Table 1. Characteristics of Focus Group Participants (N = 30), Perry and 
Wilcox Counties, Alabama, 2011
Characteristic
Perry County 
Group (n = 7)
Wilcox County 
Group 1 (n = 9)
Wilcox County 
Group 2 (n = 6)
Wilcox County 
Group 3 (n = 8)
Total (N 
= 30)
Age ≥60 y 5 2 3 2 12
Female 7 9 5 7 28
Graduated from college 3 5 2 3 13
Not employed 7 6 3 6 22
Last visited a doctor, clinic, or 
hospital <1 month ago
3 4 3 3 13
Has medical insurance 7 8 2 5 22
Regular source of health care 6 9 5 4 24a
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Characteristic
Perry County 
Group (n = 7)
Wilcox County 
Group 1 (n = 9)
Wilcox County 
Group 2 (n = 6)
Wilcox County 
Group 3 (n = 8)
Total (N 
= 30)
Takes ≥6 prescription 
medications daily for chronic 
diseases
5 5 2 1 13
 Defined as having a personal or private doctor or clinic.
 











Perceived differences in efficacy and side effects X X X X
Perception that generics are not real medicines X X X
Willingness to take generics for minor but not 
serious illnesses
X X X X
Trust and medication adherence X X X X
Perception that, although generics cost less, people 
of limited means have to settle for generics
X X X X
Appendix. Moderator Script 
 
Opening (10 minutes)
Hello. My name is [moderator name]. Today we would like to have a conversation with you about brand and generic 
prescription medicines. What we are trying to accomplish before we leave here today is to get a better understanding of 
how you feel about medications. Are there any questions?
Respond to participant questions
Let’s go over some rules. First, let’s all turn off our cell phones so we are not interrupted. So we can keep track of what 
people are saying, remember that we can only have one person talking at a time. Please do not interrupt someone when 
they are talking. Also, everything you tell us today will be kept completely confidential. We will summarize the things 
you tell us and combine it with other focus groups we are giving. One of my jobs today as the moderator is to make sure 
we discuss all of the issues we planned to discuss. If I ask you questions while you are talking, I’m not being rude; I’m 
just making sure everyone has a chance to talk and that we discuss all of the issues.
Your opinions are extremely important to us, and we want you to feel free to tell us exactly what you think. Your 
participation is completely voluntary, and you don’t have to take part in the discussion group. You can withdraw from 
the discussion at any time, for any reason.
I will be leading the discussion, and [name of assistant] will be taking notes. We will record the discussion. All 
recorded information is confidential, anonymous, and will be used only for research purposes. The recording will be 
destroyed at the end of the study.
Pass out information sheet
Please take time to read the information sheet. Go through the sheet as a group.
Begin discussion group
Ask all participants to introduce themselves. To keep it anonymous, begin recording after introductions.
Let’s begin.
Questions 1-5 (45-70 minutes)
a
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1. What does the term “generic medication” mean to you?
2. How do you feel about taking generic medications?
(probe) How well do you think generic medications work?
(probe) Do you think either generic or brand medications have more side effects, or the same number?
3. Would you switch to a generic medication from a brand medication if your doctor prescribed it?
4. For what kinds of illness (serious, chronic, or minor) would you feel most comfortable taking a generic medication?
5. What are some reasons you would be hesitant to switch from brand to generic medications?
Closure (10 minutes)
Did we miss talking about anything else important about generic drugs? Are there any final questions? Thank you for 
participating in our discussion group today. We are excited to learn about what you think.
 
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. 
Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, 
or the authors' affiliated institutions. 
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